PubMed Triage Digest — 2026-08-07

Run ID: 2026-08-07-attempt2-20260807T092314Z
Attempt: 2 of 3
Model: anthropic/claude-sonnet-4-6
Window: 1-day CRDT lookback

Executive Summary

20 articles triaged across 10 topics: 7 HIGH priority, 13 MEDIUM priority, 0 LOW priority. Topic T2 (CBC/ML hematology) returned 0 results on both primary and fallback queries. Strongest signals today: EV immune checkpoint liquid biopsy predicts ICI resistance in HCC 36–42 weeks before imaging (score 10; Gut); two Phase III readouts — POETYK PsA-1 (deucravacitinib, positive) and SKYSCRAPER-03 (tiragolumab+atezo vs. durvalumab, negative); deep learning NEPC histologic classifier validated externally at AUROC 0.921.

T1 — Hematologic Malignancies

Search: 54 total hits · 15 reviewed · 2 HIGH

HIGH Priority

PMID 42562324 ⭐⭐⭐ score=9 — Transplant Cell Ther, 2026 Aug 6
Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models.
Kungwankiattichai S, Bastola S, Rai M, Chen AI et al.
→ Multicenter real-world cohort plus prediction models for outcomes after CAR-T failure in LBCL — critical unmet need as CAR-T expands. Updated prognostic factors guide salvage therapy selection.

PMID 42561008 ⭐⭐⭐ score=9 — Hematol Oncol, 2026 Sep
Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk AML and MDS.
Lyu C, Xie T, Pu Y, Luan X et al.
→ Novel clinical approach: defines timing/dosing safety window for venetoclax post-allogeneic transplant in AML/MDS. First dedicated evidence for this emerging maintenance strategy.

MEDIUM Priority

PMID 42561659 score=7 — Int Immunopharmacol, 2026 Aug 6
Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting LSCs and MRD in AML.
Mathew AA, Raheja R, Alex PT. (Review)
→ Comprehensive review of dual LSC+MRD targeting CAR-T strategies in AML; identifies near-term clinical solutions including multiplex CAR constructs and venetoclax combinations.

PMID 42562619 score=5 — Int J Lab Hematol, 2026 Aug 6
Expression of Peripheral Blood microRNA-126 and Its Prognostic Value in Patients With Acute Myeloid Leukemia.
Zhang H et al. (title-only; conservative score)

PMID 42561705 score=5 — Hematol Transfus Cell Ther, 2026 Aug 6
Association between serum biomarkers and clinical stage in treatment-naïve chronic lymphocytic leukemia.
Khosravifarsani M et al. (title-only; conservative score)

T2 — CBC/ML Hematology

Search: 0 hits (primary) · 0 hits (fallback) · 0 articles

No articles indexed today for this topic under either primary or fallback query. No items to triage.

T3 — Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

Search: 28 total hits · 15 reviewed · 2 HIGH

HIGH Priority

PMID 42562419 ⭐⭐⭐ score=10 — Gut, 2026 Aug 6
Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.
Gorgulho J, Masood R, Buescher G et al.
→ Multiplex EV immune checkpoint profiling in 3 cohorts (n=279 total; training + validation) predicts ICI response and acquired resistance 36–42 weeks before imaging in HCC. Non-invasive, quantifiable, and clinically transformative for a tumor type where tissue biopsy is rarely performed.

PMID 42562001 ⭐⭐ score=8 — J Natl Compr Canc Netw, 2026 Aug 6
Technology-Enabled Patient and Physician Activation to Enhance Skin Cancer Screening After HCT: A Randomized Controlled Trial.
Armenian SH, Du X, Bosworth A et al.
→ RCT demonstrates digital tool-mediated skin cancer surveillance activation improves engagement in HCT survivors — high unmet need given 2–5× elevated skin cancer risk post-transplant.

MEDIUM Priority

PMID 42560195 score=7 — Mil Med, 2026 Aug 1
Artificial Intelligence/Machine Learning-Driven cfDNA Methylation Blood Test for Early Cancer Detection in Military Personnel With Environmental Toxin Exposure.
Subharam M, Koehler R, Sreedhar T.
→ Application of AI/ML cfDNA methylation MCED testing to military personnel with occupational toxic exposures; novel high-risk cohort for MCED deployment.

T4 — AI/ML in Clinical Diagnostics and Imaging

Search: 16 total hits · 15 reviewed · 1 HIGH

HIGH Priority

PMID 42560769 ⭐⭐⭐ score=9 — JCI Insight, 2026 Aug 6
Deep learning-based histologic classifiers enable molecular subtyping of metastatic prostate cancer.
Chen Z, Sayar E, Guevara D et al. (NCI/Fred Hutch/Weill Cornell/MD Anderson)
→ NEURAL-PC achieves AUROC 0.921 for neuroendocrine prostate cancer (NEPC) classification from H&E images alone using multiple instance learning. Independently validated across multicenter cohorts; prognostic value beyond NEPC; directly addresses clinical bottleneck where NEPC diagnosis currently requires expensive molecular assays.

MEDIUM Priority

PMID 42562389 score=7 — J Med Internet Res, 2026 Aug 6 (cross-listed T7)
→ AI-GTM phenotyping of 3,259 prospective AF patients; 4 phenotypes with distinct 2-year outcomes.

PMID 42561017 score=7 — PNAS, 2026 Aug 11 (cross-listed T6)
→ AI-designed PROTAC eliminates CLIP1-LTK fusion; preclinical but high novelty.

T5 — Precision Oncology and Genomic Medicine

Search: 26 total hits · 15 reviewed · 1 HIGH (via cross-topic PMID 42562419)

MEDIUM Priority

PMID 42559798 score=7 — Int J Urol, 2026 Aug
Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.
Yasuda Y, Yoshida S, Yonese I et al. (multicenter, Japan)
→ n=27, BRCA PV prevalence 14% by CGP, mOS 18.4 months consistent with trial data; supports CGP-guided olaparib use in East Asian mCRPC.

T6 — Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

Search: 117 total hits · 15 reviewed · 3 HIGH

HIGH Priority

PMID 42562209 ⭐⭐ score=8 — Ann Oncol, 2026 Aug 6
SKYSCRAPER-03: Phase III — Tiragolumab + Atezolizumab vs. Durvalumab in Stage III NSCLC after CRT.
Wakelee HA, Ahn MJ, Bradley J et al. (Genentech-sponsored)
→ Negative result. Primary endpoint not met: tiragolumab+atezo vs. durvalumab showed HR 0.96 (95% CI 0.75–1.23) for PFS in PD-L1+ patients. Median OS not estimable (atezo arm) vs. 54.8 months (durvalumab), HR 0.99. No additional benefit over SOC across PD-L1 strata. Shapes clinical strategy for TIGIT inhibitors.

PMID 42562419 ⭐⭐⭐ score=10 — Gut (primary: T3; see above)

PMID 42562324 ⭐⭐⭐ score=9 — Transplant Cell Ther (primary: T1; see above)

MEDIUM Priority

PMID 42561017 score=7 — PNAS, 2026 Aug 11
AI-driven PROTAC design overcomes oncogenic resilience by eliminating the CLIP1-LTK fusion protein.
Chen S, Duan H, Zhong S et al.
→ AI-guided PROTAC degrader for rare oncogenic CLIP1-LTK fusion; overcomes kinase inhibitor resistance; preclinical proof-of-concept published in high-impact venue.

T7 — Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

Search: 60 total hits · 15 reviewed · 0 HIGH

MEDIUM Priority

PMID 42562389 score=7 — J Med Internet Res, 2026 Aug 6
AI-Based Phenotyping of Atrial Fibrillation Through Generative Topographic Mapping: Prospective Cohort Study.
Soler Espejo E, Chen Y, Ramos-Bratos MP et al. (Lip group, Liverpool)
→ 3,259 prospective AF patients; GTM AI clustering identifies 4 phenotypes with distinct thromboembolic, bleeding, and mortality risks; external validation warranted but methodology is sound.

PMID 42562072 score=7 — Clin Res Hepatol Gastroenterol, 2026 Aug 6
Safety and Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Liver Transplant Recipients with Diabetes.
Mazzola A, Sultanik P, Rebiha A et al. (Pitié-Salpêtrière Hospital, Paris)
→ First real-world comparative data in liver transplant recipients (n=41); 90% HbA1c target achieved; 80% insulin withdrawal in post-transplant diabetes; no serious AEs. Critical gap-filling data for an immunosuppressed population excluded from major trials.

PMID 42562562 score=6 — J Clin Lipidol, 2026 Jul
Family-based interventions for optimal lipid outcomes in adults: A cluster RCT in India.
Jeemon P, Kripa SVS, Soman S et al.
→ Cluster RCT supporting scalable family-centered lipid management in South Asian LMI setting.

T8 — Aging, Longevity, and Population Health

Search: 7 total hits · 7 reviewed · 0 HIGH

MEDIUM Priority

PMID 42557844 score=6 — Biomed Res Int, 2026
Analysis of Cytological Markers of Cellular Senescence in High-Risk Cardiovascular Patients After COVID-19.
Kyryk V, Ustymenko A, Tsupykov O et al.
→ Senescence markers elevated post-COVID in cardiovascular high-risk patients; contributes to post-COVID accelerated aging literature.

PMID 42557925 score=6 — Liver Int, 2026 Sep
Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.
Rapino C, Sebastiani G, Burnside J et al.
→ Marginal structural model (causal inference) quantifies steatosis + alcohol impact on mortality in aging Canadian cohort; methodologically rigorous.

T9 — Rare Diseases with High Unmet Need

Search: 6 total hits · 6 reviewed · 0 HIGH

MEDIUM Priority

PMID 42562627 score=7 — J Med Genet, 2026 Aug 6
The British Society for Genetic Medicine guidance on managing incidental findings identified during rare disease genomic testing.
Ellard S, Hanson H, Cassidy EJ et al. (BSGM, NHS)
→ Formal national guidance recommends reporting high-penetrance actionable pathogenic variants; discourages heterozygous recessive carrier reporting; provides decision framework and cancer susceptibility gene list. Immediately applicable to NHS genomic laboratories and internationally relevant.

PMID 42558576 score=7 — Front Cardiovasc Med, 2026 Jul 22
Identifying implementation strategies to increase the early detection of cardiac amyloidosis: a pre-implementation study.
Koskan AM, Guzman-Clark J, Ball SL et al. (Arizona State/VA)
→ 23 implementation strategies identified for transthyretin CA early detection; bone scintigraphy expansion, AI-EHR integration, and specialized care teams highlighted. Cardiac amyloidosis: rare disease with now-effective therapy (tafamidis) where early diagnosis is crucial.

Sentinel Scan

Search: 560 total hits · 10 reviewed · 1 HIGH

HIGH Priority

PMID 42562758 ⭐⭐ score=8 — Ann Rheum Dis, 2026 Aug 6
Efficacy and safety of deucravacitinib (TYK2i) in psoriatic arthritis: 52-week results — Phase 3 POETYK PsA-1.
van der Heijde D, Mease PJ, Paul C et al. (Bristol Myers Squibb-sponsored)
→ Positive result. ACR20 54.2% vs 34.1% placebo at week 16 (P<0.001); structural damage inhibition and responses maintained at 52 weeks. Favorable safety: no new signals, no CV imbalances, no opportunistic infections. Deucravacitinib is the first oral TYK2-selective agent, addressing JAK inhibitor safety concerns in inflammatory disease.

Coverage Notes

†HIGH via cross-topic PMID 42562419 appearing in T5 search results.

All article scores reflect the 0–10 rubric (novelty ≤3, relevance ≤3, design_quality ≤2, population_or_unmet_need ≤2). Title-only records received conservative scores (≤5). Scores ≥8 = HIGH, 5–7 = MEDIUM.